U.S. Markets closed
  • S&P 500

    4,395.64
    +41.45 (+0.95%)
     
  • Dow 30

    34,258.32
    +338.48 (+1.00%)
     
  • Nasdaq

    14,896.85
    +150.45 (+1.02%)
     
  • Russell 2000

    2,218.56
    +32.38 (+1.48%)
     
  • Gold

    1,768.40
    -9.80 (-0.55%)
     
  • Silver

    23.03
    +0.46 (+2.05%)
     
  • EUR/USD

    1.1696
    -0.0034 (-0.2924%)
     
  • 10-Yr Bond

    1.3360
    +0.0120 (+0.91%)
     
  • Vix

    20.87
    -3.49 (-14.33%)
     
  • GBP/USD

    1.3619
    -0.0045 (-0.3282%)
     
  • USD/JPY

    109.7800
    +0.5600 (+0.5127%)
     
  • BTC-USD

    41,284.09
    -868.62 (-2.06%)
     
  • CMC Crypto 200

    1,089.55
    +49.07 (+4.72%)
     
  • FTSE 100

    7,083.37
    +102.39 (+1.47%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Here's Why You Should Retain Stryker (SYK) Stock Right Now

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Stryker Corporation SYK is well poised for growth backed by robust robotic-arm assisted surgery platform — Mako and diversified product portfolio. However, pricing pressure remains a headwind.

Shares of the company have gained 49.1% compared with the industry’s rally of 20.7% in a year’s time. Meanwhile, the S&P 500 Index has surged 40.6% in the same time frame.

Stryker, with a market capitalization of $98.99 billion, is one of the world’s largest medical device companies operating in the orthopedic market. It anticipates earnings to improve 9.6% in the next five years. Moreover, it has a trailing four-quarter earnings surprise of 15.9%, on average.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

Let’s take a closer look at the factors that substantiate the company’s Zacks Rank #3 (Hold).

What’s Deterring the Stock?

An unfavorable pricing environment poses a persistent threat to Stryker’s core businesses. In fact, pricing in first-quarter 2021 had an impact of 0.9% on the top line. Consequently, pricing pressure remains a cause of concern.

What’s Favoring Growth?

Mako is Stryker’s robotic-arm assisted surgery platform. The company continues to witness strong demand for Mako and healthy order book, courtesy of the platform’s unique features despite financial constraints stemming from the COVID-19 pandemic. This, in turn, positions it well to sustain momentum in robot sales and recon share market gains.

During 2020, the company’s Mako install base saw growth of 33%, and beat another milestone with more than 100 robots sold and installed in the fourth quarter of 2020. Thereby, the company continues to focus on continued expansion of Mako. This growth reflects demand for Stryker’s differentiated Mako robotic technology. This momentum continued in the first quarter of 2021 as well with advancement in the international markets.

For 2021, the company’s Mako order book remains solid, and is in sync with its aim of continuous share gains in both hips and knees.

Additionally, Stryker has a diversified product portfolio. Its wide range of products shields the company against any significant sales shortfall during economic turmoil. Its significant exposure in robotics, Artificial Intelligence for health care and Medical Mechatronics has provided the company with a competitive edge in the MedTech space. Stryker’s portfolio includes products like Hip, Knee and Mako robotic-arm assisted surgeries.

Per management, the company’s sustained support for customers and focus on innovation will position it well for growth, as the pandemic eventually subsides. In the first quarter, Stryker’s adjusted R&D expenses were 6.8% of net sales, which highlights the its sustained commitment toward innovation. Per management, this is likely to drive new product launches.

Estimates Trend

For 2021, the Zacks Consensus Estimate for revenues is pegged at $17.14 billion, indicating an improvement of 19.4% from the previous year. The same for earnings stands at $9.18, suggesting growth of 23.6% from the year-ago reported figure.

Stocks to Consider

Some better-ranked stocks from the broader medical space are Veeva Systems Inc. VEEV, DaVita Inc. DVA and Encompass Health Corporation EHC, each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Veeva Systems’ long-term earnings growth rate is estimated at 15.8%.

DaVita’s long-term earnings growth rate is estimated at 14.4%.

Encompass Health’s long-term earnings growth rate is projected at 17.3%.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Stryker Corporation (SYK) : Free Stock Analysis Report

DaVita Inc. (DVA) : Free Stock Analysis Report

Veeva Systems Inc. (VEEV) : Free Stock Analysis Report

Encompass Health Corporation (EHC) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research